Connect with us
[ad_1] STUART, Fla., Feb. 1, 2024 /PRNewswire/ — Stuart Therapeutics, Inc. (“Stuart”), a clinical-stage biopharmaceutical company with candidate therapeutics in various phases of clinical development, today announced...
[ad_1] Updated Dec 27, 2023, 7:34 am EST / Original Dec 27, 2023, 4:26 am EST Stock futures traded slightly lower Wednesday after the S&P 500 finished...
[ad_1] Bristol Myers Squibb will acquire radiopharmaceutical therapeutics company RayzeBio for $62.50 a share in cash. Continue reading this article with a Barron’s subscription. View Options...
[ad_1] Two weeks ago, bluebird bio secured Food and Drug Administration approval for its gene therapy for sickle cell disease, a significant milestone for the roughly...
[ad_1] Dec 19, 2023, 4:31 am EST Stock futures traded flat Tuesday, a day after the S&P 500 finished up 0.5% and moved closer to its...
[ad_1] Stock futures pointed higher Friday as Wall Street returned for a shortened trading session following the Thanksgiving holiday. Retailers will be in focus on Black...
[ad_1] Ardelyx Inc. ARDX, -0.58% on Tuesday won its long fight for U.S. regulatory approval of a treatment designed to help patients with chronic kidney disease....
[ad_1] Updated Oct. 17, 2023 2:47 am ET Lonza Group warned that its profitability will take a hit next year from losing revenue from an agreement...
[ad_1] Pfizer Stock Gains After Earnings Beat. Revenue and Outlook Aren’t So Good. [ad_2] Source link
[ad_1] This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com. https://www.barrons.com/articles/stock-market-movers-fb3791aa Updated...
[ad_1] By Anthony O. Goriainoff AstraZeneca said Thursday that its and MSD’s Lynparza cancer treatment had been approved in the U.S. for the treatment of metastatic...
[ad_1] Pfizer Agrees to Buy Seagen for $43 Billion [ad_2] Source link
[ad_1] A flurry of announcements relating to COVID vaccines dominated headlines on the pandemic on Monday, with Moderna telling investors it expects to generate some $5...
[ad_1] Danish biotechnology companies Novozymes AS NZYM.B, -10.74% and Chr. Hansen Holding AS CHR, +25.98% said Monday they have agreed to merge, creating a biological solutions...
[ad_1] WSJ News Exclusive Business U.S. biotechnology company was the last of three suitors standing in an auction for Horizon [ad_2] Source link
[ad_1] A fresh analysis of data on the immune response generated by the bivalent COVID-19 booster showed strong results against the newer omicron sublineages, Pfizer and...
[ad_1] First the good news: Pfizer Inc. and Germany-based partner BioNTech SE said updated trial data for their omicron BA.4/BA.5-adapted bivalent booster showed a “substantially higher”...
[ad_1] Pfizer Inc. PFE, +4.17% said Thursday that it plans to sell the COVID-19 shot it developed with BioNTech SE BNTX, +7.14% for $110 to $130...